How Drug Prices Are Sending Mixed Signals in 2026

The prescription drug cost story in 2026 is not a single headline. It is two stories running simultaneously - one in which meaningful savings are reaching millions of Medicare patients for the first time, and another in which drugmakers are raising prices on hundreds of medications while those negotiations are celebrated. For Americans navigating the pharmacy counter, understanding which story applies to them depends entirely on which side of a narrow eligibility line they stand.

The Medicare Savings That Are Real

The first ten drugs subject to Medicare price negotiations produced an average of 51 percent reductions in out-of-pocket costs for Part D enrollees, according to AARP research. CBS News confirmed the program generated an estimated $6 billion in annual savings for the Medicare system as a whole. For a patient taking Eliquis, a common blood thinner, or Jardiance for diabetes, the change at the pharmacy counter in January 2026 was concrete and immediate.

CBS described this as the first time the United States has negotiated drug prices at a national level, as every other developed country has long done. A second cycle covering Ozempic, Wegovy, and 13 other medications reached agreement in 2025, with those prices taking effect in 2027. CMS announced in March 2026 that a third cycle of negotiations for 15 more drugs would take place this year.

The Price Increases Arriving Alongside the Savings

At the same time those negotiated prices took effect, drugmakers raised list prices on more than 350 medications in the opening weeks of 2026 - up from approximately 250 the prior year - according to CNN Business reporting. Pfizer raised prices on roughly 80 drugs, including a 15 percent increase on its COVID vaccine. The median increase across the wave was approximately 4 percent.

Those increases do not apply to the negotiated Medicare drugs, but they affect the broad population of Americans who use medications not yet subject to negotiation - which is to say, the vast majority of prescriptions being filled in the United States today.

Who the Savings Reach - and Who They Don’t

The Medicare negotiated prices apply specifically to Medicare Part D enrollees using the selected drugs. For Americans under 65, for those with employer-sponsored insurance, or for those whose medications were not selected for negotiation, the savings structure does not apply. A KFF poll found that approximately 60 percent of American adults report worrying about affording prescription drugs - a figure that reflects how broad the concern is relative to the narrower scope of the current savings program.

CBS News also noted that some of Trump’s parallel drug pricing initiatives - including deals announced with individual pharmaceutical executives - carry limited practical benefit for most patients and require active knowledge of specialized discount programs to access.

The Longer-Term Picture

The One Big Beautiful Bill Act’s provision exempting rare disease drugs from future negotiations places a boundary on the program’s expansion. Legislative and legal challenges to the negotiation framework continue, though courts have so far rejected industry challenges to the program’s constitutionality.

For the roughly nine million Medicare enrollees currently taking the ten negotiated drugs, the savings represent a genuine and meaningful change. For the broader population of American patients managing prescription costs, 2026 is a year in which the trajectory of drug pricing looks different depending on which part of the system you rely on.

References: Drug Prices Trumprx | Drug Price Increases 2026